Retatrutide vs Semaglutide: How Does the Triple Agonist Compare?

Retatrutide simultaneously activates three receptors: GLP-1 for appetite suppression and insulin regulation, GIP for enhanced incretin signaling, and glucagon for increased energy expenditure and fat oxidation. This triple mechanism attacks obesity from multiple angles — reducing caloric intake while boosting caloric output.

The glucagon component also drives remarkable liver fat reductions, making retatrutide particularly interesting for NAFLD research.

Semaglutide is the established GLP-1 agonist standard. It powerfully suppresses appetite, improves insulin sensitivity, and slows gastric emptying. With FDA approval for both diabetes (Ozempic) and obesity (Wegovy), plus an oral formulation (Rybelsus), it has the broadest clinical evidence base of any incretin therapy.

The SELECT trial also demonstrated cardiovascular mortality reduction — a benefit beyond weight loss alone.

Weight loss magnitude: Retatrutide's 24.2% in Phase II substantially exceeds semaglutide's 15-17%. The gap is likely due to the added GIP and glucagon mechanisms.

Energy expenditure: Retatrutide is unique in increasing resting energy expenditure through glucagon receptor activation. Semaglutide primarily reduces intake without boosting output.

Cardiovascular data: Semaglutide has proven CV mortality reduction (SELECT trial). Retatrutide has no cardiovascular outcomes data yet.

Accessibility: Semaglutide is widely available, well-understood, and comes in oral form. Retatrutide is years from approval.

For available, proven, flexible treatment with extensive safety and CV data, semaglutide remains the standard. For frontier obesity research targeting maximum weight loss and metabolic improvement, retatrutide's triple mechanism represents the most promising advance in the pipeline.

Research-grade semaglutide is available from Ascension Peptides with verified third-party testing. Check their catalog for the latest available peptides.